Literature DB >> 1486018

Alteration of blood pressure regulation and cerebrovascular disorders in the elderly.

A Shuaib1.   

Abstract

The objective of this study was to review the available data on the effects of management of hypertension on stroke in the elderly. MED-LINE was searched for articles published from 1967 to 1991 for articles on hypertension and hypotension. The following "key words" were used to limit our search to relevant studies: "stroke", "cerebrovascular disease", "elderly", "hypertension", "hypotension", "drug trials in hypertension", "complications of acute stroke", and "stroke management". Original articles with data related to the effects of hypertension management or complications of hypotension were reviewed in detail. Of about 900 papers reviewed, 121 were selected for this review. These papers specifically addressed the long-term prognosis of subjects treated with antihypertensive medications, the prognosis after TIA or stroke, and complications of aggressive antihypertensive therapy. The incidence of hypertension increases with age. Hypertension is the most important correctable risk factor for stroke. Most studies on stroke prevention in asymptomatic hypertension (primary prevention) have shown clear benefits (including management of systolic hypertension in the elderly). Data on stroke prevention in patients with TIAs (secondary prevention) is limited but suggests that management of hypertension will decrease the risk of stroke in such patients. Patients with completed stroke who are hypertensive should have very careful management of their hypertension as they may be at risk for hypotensive complications. Sudden reduction in blood pressure in the elderly (especially in the presence of pseudohypertension) increases the risk of symptomatic cerebral hypoperfusion and stroke. Management of hypertension in the elderly is effective in stroke prevention. Because of the real risk of a sudden decrease in cerebral perfusion, pressure reduction should be done slowly and with care.

Entities:  

Mesh:

Year:  1992        PMID: 1486018

Source DB:  PubMed          Journal:  Cerebrovasc Brain Metab Rev        ISSN: 1040-8827


  6 in total

1.  Effects of melatonin on rat pial arteriolar diameter in vivo.

Authors:  O Régrigny; P Delagrange; E Scalbert; I Lartaud-Idjouadiene; J Atkinson; J M Chillon
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study.

Authors:  J J Claus; M M Breteler; D Hasan; E P Krenning; M L Bots; D E Grobbee; J C van Swieten; F van Harskamp; A Hofman
Journal:  Eur J Nucl Med       Date:  1996-06

3.  Dynamic Autoregulation Testing Does Not Indicate Changes of Cerebral Blood Flow Before and After Resection of Small- and Medium-Sized Cerebral AVM.

Authors:  Carsten Stüer; Toshiki Ikeda; Michael Stoffel; Carlo Schaller; Bernhard Meyer
Journal:  Transl Stroke Res       Date:  2011-03       Impact factor: 6.829

4.  Impact of treatment with melatonin on cerebral circulation in old rats.

Authors:  François Dupuis; Olivier Régrigny; Jeffrey Atkinson; Patrick Limiñana; Philippe Delagrange; Elizabeth Scalbert; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

5.  Corneal Confocal Microscopy detects a Reduction in Corneal Endothelial Cells and Nerve Fibres in Patients with Acute Ischemic Stroke.

Authors:  Adnan Khan; Saadat Kamran; Naveed Akhtar; Georgios Ponirakis; Hamad Al-Muhannadi; Ioannis N Petropoulos; Shumoos Al-Fahdawi; Rami Qahwaji; Faheem Sartaj; Blessy Babu; Muhammad Faisal Wadiwala; Ashfaq Shuaib; Rayaz A Malik
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

6.  Corneal nerve and endothelial cell damage in patients with transient ischemic attack and minor ischemic stroke.

Authors:  Hoda Gad; Adnan Khan; Naveed Akhtar; Saadat Kamran; Ahmed El-Sotouhy; Soha R Dargham; Ioannis N Petropoulos; Georgios Ponirakis; Ashfaq Shuaib; Leopold J Streletz; Rayaz A Malik
Journal:  PLoS One       Date:  2019-03-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.